Rabbit Polyclonal Anti-TERT antibody (STJ98964)

$99.00$319.00

Reactivity: Human
Applications: WB, IHC, ELISA
Conjugation: Unconjugated
Supplier: St John’s Laboratory Ltd.

Clear
-$50 as credit for submitting review for primary antibody
Shipping notice:
Product will be delivered in 6 to 8 Business Days

Antibody Validation Project, Antibody Trial Sample, Antibody Free Sample for your own antibody validation and submitting antibody reviews, AntibodyPlus

Rabbit Polyclonal Anti-TERT antibody (STJ98964)

Supplier: St John’s Laboratory Ltd.

Recommended applications: WB, ELISA

Recommended dilution: WB 1:500-2000; ELISA 1:10000-20000

Recommended protocols: check protocols

Image descriptions:

Click or hover above images to see image description for Anti-TERT antibody (STJ98964).

Alternative names:

Check alternative names for the antibody

Expand

|CMM9 antibody|DKCA2 antibody|DKCB4 antibody|EST2 antibody|HEST2 antibody|htert antibody|hTRT antibody|PFBMFT1 antibody|TCS1 antibody|Telomerase associated protein 2 antibody|Telomerase catalytic subunit antibody|Telomerase reverse transcriptase antibody|Telomerase-associated protein 2 antibody|Telomere Reverse Transcriptase antibody|TERT antibody|TERT_HUMAN antibody|TP2 antibody|TRT antibody|Anti-Telomerase reverse transcriptase antibody [Y182] (ab32020)
SCBT cat No:

Name

Anti-TERT antibody

Catalogue No.

STJ98964

Reactivity

Human

Specificity

Anti-TERT antibody detects endogenous TERT.

Immunogen

Synthetic peptide from human protein at AA range: 222-298.

Host

Rabbit

Applications

WB, ELISA

Recommended dilution

WB 1:500-2000; ELISA 1:10000-20000

Clonality

Polyclonal

Conjugation

Unconjugated

Isotype

IgG

Molecular weight

126kDa

Formulation

Anti-TERT antibody was tube-contained in liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration

1 mg/ml

Purification

Anti-TERT antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Storage

-20 Celsius degree. Avoid repeated freeze/thaw cycles.

Alternative antibody names

CMM9 antibody, DKCA2 antibody, DKCB4 antibody, EST2 antibody, HEST2 antibody, htert antibody, hTRT antibody, PFBMFT1 antibody, TCS1 antibody, Telomerase associated protein 2 antibody, Telomerase catalytic subunit antibody, Telomerase reverse transcriptase antibody, Telomerase-associated protein 2 antibody, Telomere Reverse Transcriptase antibody, TERT antibody, TERT_HUMAN antibody, TP2 antibody, TRT antibody

Database links

UniProt/Swiss-Prot:O14746

Protein function

Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3′-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5′-TTAGGG-3′. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis. .

Protein tissue specificity

Expressed at a high level in thymocyte subpopulations, at an intermediate level in tonsil T-lymphocytes, and at a low to undetectable level in peripheral blood T-lymphocytes. .

Involvement in disease

Note=Activation of telomerase has been implicated in cell immortalization and cancer cell pathogenesis.; Aplastic anemia (AA) [MIM:609135]: A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements. It is characterized by peripheral pancytopenia and marrow hypoplasia. . Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; Note=Genetic variations in TERT are associated with coronary artery disease (CAD).; Dyskeratosis congenita, autosomal dominant, 2 (DKCA2) [MIM:613989]: A rare multisystem disorder caused by defective telomere maintenance. It is characterized by progressive bone marrow failure, and the clinical triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common but variable features include premature graying, aplastic anemia, low platelets, osteoporosis, pulmonary fibrosis, and liver fibrosis among others. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Pulmonary fibrosis, and/or bone marrow failure, telomere-related, 1 (PFBMFT1) [MIM:614742]: A disease associated with shortened telomeres. Pulmonary fibrosis is the most common manifestation. Other manifestations include aplastic anemia due to bone marrow failure, hepatic fibrosis, and increased cancer risk, particularly myelodysplastic syndrome and acute myeloid leukemia. Phenotype, age at onset, and severity are determined by telomere length. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Dyskeratosis congenita, autosomal recessive, 4 (DKCB4) [MIM:613989]: A severe form of dyskeratosis congenita, a rare multisystem disorder caused by defective telomere maintenance. It is characterized by progressive bone marrow failure, and the clinical triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common but variable features include premature graying, aplastic anemia, low platelets, osteoporosis, pulmonary fibrosis, and liver fibrosis among others. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Pulmonary fibrosis, idiopathic (IPF) [MIM:178500]: A lung disease characterized by shortness of breath, radiographically evident diffuse pulmonary infiltrates, and varying degrees of inflammation and fibrosis on biopsy. In some cases, the disorder can be rapidly progressive and characterized by sequential acute lung injury with subsequent scarring and end-stage lung disease. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; Melanoma, cutaneous malignant 9 (CMM9) [MIM:615134]: A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites. . Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.

Protein sequence and domain

Belongs to the reverse transcriptase family. Telomerase subfamily. ; Contains 1 reverse transcriptase domain. The primer grip sequence in the RT domain is required for telomerase activity and for stable association with short telomeric primers.; The RNA-interacting domain 1 (RD1)/N-terminal extension (NTE) is required for interaction with the pseudoknot-template domain of each of TERC dimers. It contains anchor sites that bind primer nucleotides upstream of the RNA-DNA hybrid and is thus an essential determinant of repeat addition processivity.; The RNA-interacting domain 2 (RD2) is essential for both interaction with the CR4-CR5 domain of TERC and for DNA synthesis.

Protein post-translational modifications

Phosphorylation at Tyr-707 under oxidative stress leads to translocation of TERT to the cytoplasm and reduces its antiapoptotic activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention. Phosphorylation at Ser-227 by the AKT pathway promotes nuclear location. Phosphorylation at the G2/M phase at Ser-457 by DYRK2 promotes ubiquitination by the EDVP complex and degradation. .; Ubiquitinated by the EDVP complex, a E3 ligase complex following phosphorylation at Ser-457 by DYRK2. Ubiquitinated leads to proteasomal degradation. In case of infection by HIV-1, the EDVP complex is hijacked by HIV-1 via interaction between HIV-1 Vpr and DCAF1/VPRBP, leading to ubiquitination and degradation. .

Protein cellular localization

Nucleus, nucleolus . Nucleus, nucleoplasm. Nucleus. Chromosome, telomere. Cytoplasm. Nucleus, PML body. Note=Shuttling between nuclear and cytoplasm depends on cell cycle, phosphorylation states, transformation and DNA damage. Diffuse localization in the nucleoplasm. Enriched in nucleoli of certain cell types. Translocated to the cytoplasm via nuclear pores in a CRM1/RAN-dependent manner involving oxidative stress-mediated phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2 retains TERT in the nucleus. Translocated to the nucleus by phosphorylation by AKT.

Research area

All research areas>Transcription Regulators>TERT
(View all antibody categories related to Transcription Regulators)

Note

AntibodyPlus can customize Anti-TERT antibody according to your requirement, including bulk product size,etc. Please contact info@antibodyplus.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.

Supplier

St John’s Laboratory Ltd.

Product type

Primary antibody

Reviews


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review

There are no reviews for this product yet.
By submitting a review, get following benefits:

1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!

view database submit reviews
 

Immunohistochemical analysis of paraffin embedded Human kidney tissue

1: TERT Polyclonal Antibody was diluted at 1:200 (4 degree Celsius,overnight).
2: Sodium citrate pH 6.0 was used for antibody retrieval (>98 degree Celsius,20min).
3: Secondary antibody was diluted at 1:200 (room temperature, 30min). Negative control was used by secondary antibody only.


Welcome to AntibodyPlus!